Loading...

US And Asian Expansion Will Unlock Pharmaceutical Market Potential

Published
30 Mar 25
Updated
28 Aug 25
AnalystConsensusTarget's Fair Value
CHF 84.00
30.6% undervalued intrinsic discount
04 Sep
CHF 58.30
Loading
1Y
-26.0%
7D
-5.0%

Author's Valuation

CHF 84.0

30.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on28 Aug 25

With no changes in key valuation metrics such as the discount rate (4.16%) and future P/E (28.70x), SKAN Group’s consensus analyst price target remains unchanged at CHF84.00. What's in the News SKAN Group AG confirmed its full-year 2025 earnings guidance, targeting sales growth in the mid-teens.

Shared on01 May 25
Fair value Decreased 5.32%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.57%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.